Data / Form D filings / Relypsa Inc
Relypsa Inc: Form D filings
Relypsa Inc, a pharmaceuticals company in Santa Clara, CA, filed 7 Form D notices with the SEC between 2010 and 2012. The latest, on December 11, 2012, reports $65 million sold of a $80 million offering to 15 investors.
Find out what Relypsa Inc does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 5301 PATRICK HENRY DRIVE, Santa Clara, CA, 95054
- Phone
- (408) 200-9500
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506
- SEC identifier (CIK)
- 1416792
The full lists. Form D filings in California: 5,891 rows, $138.91, or the new rows each week for $19 a month. Form D filings in Pharmaceuticals: 346 rows, $17.30, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Dec 11, 2012 | Amendment | $80,000,200 | $65,000,192 | $15,000,008 | 15 | Jul 26, 2012 | sec.gov |
| Oct 5, 2012 | Amendment | $80,000,200 | $62,412,304 | $17,587,896 | 14 | Jul 26, 2012 | sec.gov |
| Aug 10, 2012 | New notice | $80,000,200 | $49,677,652 | $30,322,548 | 13 | Jul 26, 2012 | sec.gov |
| Aug 8, 2011 | Amendment | $70,129,747 | $70,129,747 | $0 | 12 | Sep 3, 2010 | sec.gov |
| Sep 14, 2010 | New notice | $70,129,747 | $35,129,747 | $35,000,000 | 12 | Sep 3, 2010 | sec.gov |
| Jul 30, 2010 | Amendment | $6,000,060 | $6,000,060 | $0 | 11 | Apr 27, 2010 | sec.gov |
| May 3, 2010 | New notice | $4,000,040 | $4,000,040 | $0 | 11 | Apr 27, 2010 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Jonathan M. Silverstein | Director | |
| Gerrit Klaerner | Executive Officer, Director | |
| Thomas M. Schuetz | Director | |
| Scott M. Rocklage | Director | |
| Ron M. Hunt | Director | |
| Paul M. Hastings | Director | |
| Wilhelm M. Stahl | Executive Officer | |
| Jerry M. Buysse | Executive Officer | |
| Klaus M. Veitinger | Director | |
| Ronald Krasnow | Executive Officer | |
| Lance M. Berman | Executive Officer | |
| Claire M. Lockey | Executive Officer |
Other pharmaceuticals companies in California that filed recently
- Anvion Bio, Inc. $100,000 · Oct 7, 2026
- Aqur Biosciences, Inc. $1.5 million · Sep 18, 2026
- BTB Therapeutics, Inc. $8.9 million · Aug 12, 2026
Every Form D from the week of Dec 10, 2012 · All recent filings in California · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Relypsa Inc reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.